Top Analyst Picks w/ Strong Stock Buyback Activity
By The Online Investor Staff, updated Sun., May. 12, 7:17 PM
| This Slide: #4 of 100 |
#97 : Amgen Inc (NASDAQ:AMGN)
Amgen is a biotechnology company that focuses on discovering, developing, manufacturing and delivering human therapeutics. Co.'s principal products are Enbrel® (etanercept), Prolia® (denosumab), Otezla® (apremilast), XGEVA® (denosumab), Neulasta® (pegfilgrastim), Aranesp® (darbepoetin alfa), Repatha® (evolocumab), KYPROLIS® (carfilzomib) and Nplate® (romiplostim). Co. also markets a number of other products, including among other, MVASI® (bevacizumab-awwb), Vectibix® (panitumumab), KANJINTI® (trastuzumab-anns), EVENITY® (romosozumab-aqqg), EPOGEN® (epoetin alfa), BLINCYTO® (blinatumomab), AMGEVITA™ (adalimumab), Aimovig® (erenumab-aooe), Parsabiv® (etelcalcetide) and NEUPOGEN® (filgrastim).
Amgen SEC Filing Email Alerts Service
In the past twelve months, Amgen Inc has repurchased a substantial amount of its outstanding shares — a lower share count means that the remaining shares will each enjoy a large slice of the company's future earnings. 
Open the AMGN Page at The Online Investor »
|
||||||||||||||||||||||||
Open the AMGN Page at The Online Investor (in a new window) »
AMGN Average Broker Rec.
  
|
 Buy (2.84 out of 4) 20th percentile
(ranked lower than approx. 80% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |
 Free AMGN Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
| Avg. Broker Rec.
|
Buy (2.84 out of 4) 20th percentile
(ranked lower than approx. 80% of all stocks covered)
Analysts' Target Price: AMGN Stock Forecast Based on Zacks ABR data; powered by Xignite |
